atazanavir sulfate has been researched along with tenofovir in 136 studies
| Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (tenofovir) | Trials (tenofovir) | Recent Studies (post-2010) (tenofovir) |
|---|---|---|---|---|---|
| 1,102 | 246 | 590 | 5,178 | 940 | 3,806 |
| Protein | Taxonomy | atazanavir sulfate (IC50) | tenofovir (IC50) |
|---|---|---|---|
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.38 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 33 (24.26) | 29.6817 |
| 2010's | 94 (69.12) | 24.3611 |
| 2020's | 9 (6.62) | 2.80 |
| Authors | Studies |
|---|---|
| Feinberg, J | 1 |
| Gallant, JE | 1 |
| Boyle, BA | 1 |
| Aboulker, JP; Calvez, V; Chazallon, C; Clavel, F; Gérard, L; Girard, PM; Piketty, C; Taburet, AM; Vincent, I | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; Rightmire, A; Rodriguez, C; Sankoh, S; Wilber, R | 1 |
| Harris, M; Montaner, JS | 1 |
| Barrail, A; Goujard, C; Le Tiec, C; Taburet, AM | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; McLaren, C; Odeshoo, L; Rightmire, A; Rodriguez, C; Wirtz, V | 1 |
| Aboulker, JP; Calvez, V; Chazallon, C; Clavel, F; Gérard, L; Girard, PM; Madelaine-Chambrin, I; Marcelin, AG; Molina, JM; Piketty, C; Taburet, AM | 1 |
| Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O | 1 |
| Mentré, F; Panhard, X; Piketti, C; Taburet, AM | 1 |
| Piacenti, FJ | 1 |
| Blanche, S; Delaugerre, C; Jullien, V; Macassa, E; Rouzioux, C; Teglas, JP; Tréluyer, JM; Veber, F | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Chmiel, JS; Moorman, A; Wood, KC; Young, B | 1 |
| Ambuhl, P; Huber, M; Keusch, G; Moch, H; Moddel, M; Opravil, M; Pfammatter, R; Schmid, S; Varga, Z; Wuthrich, RP | 1 |
| Birnkrant, DB; Chan-Tack, KM; Struble, KA; Truffa, MM | 1 |
| Aboulker, JP; Chazallon, C; Gérard, L; Girard, PM; Piketty, C; Taburet, AM | 1 |
| Dauer, B; Haberl, A; Harder, S; Klauke, S; Lutz, T; Staszewski, S; von Hentig, N | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Cunningham, CK; Fletcher, CV; Flynn, PM; Harris, DR; Havens, PL; Kapogiannis, BG; Kiser, JJ; Liu, NX; Major-Wilson, H; Muenz, LR; Viani, RM; Wilson, CM | 1 |
| Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
| Ceccarelli, G; D'Ettorre, G; Massetti, AP; Mastroianni, CM; Vullo, V; Zaffiri, L | 1 |
| Calabresi, A; Carosi, G; Costarelli, S; Izzo, I; Lapadula, G; Quiros-Roldan, E; Torti, C | 1 |
| González-Mena, A; Guelar-Grimberg, A; Knobel-Freud, H; Vallecillo-Sánchez, G | 1 |
| Barreiro, P; García-Gascó, P; González-Pardo, G; Jiménez-Nácher, I; Maida, I; Morello, J; Parra, A; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Moreno, V; Valencia, ME | 1 |
| Agud, JL; Cervero, M; García-Benaya, E; Mon, C; Navas, E | 1 |
| Cope, D; Iskander, E; Mikhail, N | 1 |
| Abeli, C; Bonfanti, P; Gianelli, E; Giuntini, R; Grosso, C; Madeddu, G; Marconi, P; Martinelli, C; Palvarini, L; Pellicano, G; Penco, G; Quirino, T; Ricci, E; Vichi, F | 1 |
| Chetchotisakd, P | 1 |
| Bonora, S; Calcagno, A; D'Avolio, A; Lanzafame, M; Penco, G; Perri, GD; Tettoni, MC | 1 |
| Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| DeJesus, E; Fischl, MA; Horton, JH; Lancaster, CT; Pakes, GE; Pappa, KA; Ross, LL; Smith, KY; Weinberg, WG | 1 |
| Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R | 1 |
| Beniowski, M; De Wit, S; Gatell, J; Kirk, O; Ledergerber, B; Lundgren, JD; Mocroft, A; Phillips, AN; Reiss, P; Sedlacek, D | 1 |
| Bansi, L; Campbell, LJ; Cheserem, E; Hendry, BM; Ibrahim, F; Naftalin, C; Post, FA; Roe, J; Sabin, C | 1 |
| Asensi, V; Miró, JM; Rodríguez-Guardado, A; Tuset, M | 1 |
| Cooper, RD; Tonelli, M | 1 |
| Basar, M; Best, BM; Burchett, SK; Capparelli, EV; Hawkins, E; Hu, C; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM | 1 |
| Bentley, TG; Broder, MS; Chang, EY; Juday, T; Uy, J | 1 |
| Bracciale, L; Cauda, R; D'Avino, A; De Luca, A; Di Giambenedetto, S; Doino, M; Fabbiani, M; Marzocchetti, A; Navarra, P | 1 |
| Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S | 1 |
| Bonnet, F; Cazanave, C; Dabis, F; Dauchy, FA; de La Faille, R; Dupon, M; Greib, C; Lawson-Ayayi, S; Mehsen, N; Miremont-Salamé, G; Rigothier, C | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S | 1 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Blanche, S; Dollfus, C; Firtion, G; Foissac, F; Hirt, D; Laurent, C; Treluyer, JM; Urien, S | 1 |
| Acosta, EP; Britto, P; Carey, V; Graham, B; Hazra, R; Jean-Philippe, P; King, JR; Wiznia, A; Yogev, R | 1 |
| Baietto, L; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Siccardi, M; Simiele, M; Tettoni, M; Trentini, L | 1 |
| Farajallah, A; McGrath, D; Sheppard, L; Uy, J; Wirtz, V; Yang, R | 1 |
| Bertz, R; Boffito, M; Child, M; Chung, E; Kashuba, A; Mahnke, L; Patterson, K; Tebas, P; Wang, X; Wu, Y; Zhang, J; Zhu, L | 1 |
| Chuck, SL; Cohen, C; Elion, R; Gathe, J; Hawkins, T; Kearney, BP; Liu, HC; Mathias, AA; Shalit, P; Warren, DR | 1 |
| Allavena, C; Dejesus, E; Fernandez Garcia, E; Fisher, M; Hardy, WD; Jackson, AG; Jayaweera, DT; Katlama, C; Mauss, S; Moyle, GJ; Raffi, F; Reiss, P; Slama, L; van Eeden, A; Vrouenraets, SM; Wit, FW | 1 |
| Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N | 1 |
| Ananthakrishnan, S; Garg, A; Levine, D | 1 |
| Abraham, B; Bélec, L; Charpentier, C; Dandy, M; De Dieu Longo, J; Grésenguet, G; Matta, M; Mbelesso, P; Moussa, S; Péré, H | 1 |
| Albini, L; Bellagamba, R; Calabresi, A; Cesana, BM; Fezza, R; Focà, E; Gotti, D; Guaraldi, G; Izzo, I; Lapadula, G; Maggi, P; Manili, L; Motta, D; Narciso, P; Quiros-Roldan, E; Sighinolfi, L; Torti, C | 1 |
| Caro-Vega, Y; Crabtree-Ramírez, B; López-Martínez, A; O'Brien, NM; Sierra-Madero, J | 1 |
| Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L | 1 |
| Cooper, DA; Duncombe, C; Emery, S; Gill, JM; Kerr, SJ; Li, PC; Puls, R; Taylor-Robinson, SD; Winston, A | 1 |
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Fernandez, VA; Reiser, IW; Spitalewitz, S; Thomas, DB | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Schäfer, J; Vernazza, P; Weber, R; Young, J | 1 |
| Aguilar-Bernier, M; Del Boz, J; Fernández-Morano, T; Fúnez-Liébana, R | 1 |
| Bloom, A; Brown, TT; Daar, ES; Fedarko, N; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C | 1 |
| Engsig, FN; Feldt-Rasmussen, B; Gerstoft, J; Kirk, O; Kronborg, G; Obel, N; Pedersen, C; Rasch, MG | 1 |
| Cheng, AK; DeJesus, E; Gathe, J; Henry, K; Kearney, BP; Molina, JM; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X; White, K; Yale, K | 1 |
| Pommer, P | 1 |
| Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A | 1 |
| Borderi, M; Calza, L; Colangeli, V; Di Bari, MA; Magistrelli, E; Manfredi, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Savic, RM; Taburet, AM; Verstuyft, C; Vrijens, B | 1 |
| Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB | 1 |
| Hayashi, T; Ikeda, H; Ishida, T; Kunimoto, Y; Miyamoto, A; Nakata, H; Noda, N; Okazaki, M; Shinomura, Y; Takahashi, S; Touda, N; Yasui, H | 1 |
| Craig, C; Fätkenheuer, G; Heera, J; Leal, M; McFadyen, L; Mildvan, D; Mills, A; Podzamczer, D; Portsmouth, S; Rinehart, AR; Than, S; Valdez, H; Valluri, SR; Vourvahis, M | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Bendayan, R; Hoque, MT; Kis, O; Walmsley, SL; Zastre, JA | 1 |
| Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R | 1 |
| Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X | 1 |
| Bigliano, P; Bonora, S; Bramato, C; Calcagno, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Libanore, V; Motta, I; Orofino, G; Orsucci, E; Salassa, B; Simiele, M; Tettoni, MC | 1 |
| Best, BM; Burchett, SK; Byroads, M; Caparelli, E; Cressey, TR; Hawkins, E; Kreitchmann, R; Mirochnick, M; Rossi, S; Shapiro, DE; Smith, E; Stek, A; Wang, J; Watts, DH | 1 |
| Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Parienti, JJ; Taburet, AM; Vigan, M; Vrijens, B | 1 |
| Baril, JG; Fournier, C; Higgins, N; Lalonde, R; Sheehan, NL; Thibeault, D; Thomas, R | 1 |
| Cahn, P; Sued, O | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; Callebaut, C; Cheng, AK; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, Y; Moyle, G; Rhee, MS; Rizzardini, G; Szwarcberg, J; Zhong, L | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Higasa, S; Horiba, M; Ishisaka, M; Kaneda, S; Kikuchi, Y; Koibuchi, T; Komatsu, H; Matsushita, S; Mitsuya, H; Naito, T; Nishijima, T; Oka, S; Tachikawa, N; Takada, K; Takano, M; Tanabe, Y; Tateyama, M; Uchiumi, H; Ueda, M; Yamamoto, M; Yokomaku, Y; Yoshida, M | 1 |
| Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M | 1 |
| Feldt-Rasmussen, B; Gerstoft, J; Helleberg, M; Kronborg, G; Larsen, CS; Obel, N; Pedersen, C; Pedersen, G; Rasch, MG | 1 |
| Arai, M; Satoh, M; Tanaka, H; Tomoda, Y; Wada, T; Yago, K | 1 |
| DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ | 1 |
| Duan, J; Freeling, JP; Ho, RJ; Koehn, J; Shu, C | 1 |
| Ananworanich, J; Bunupuradah, T; Keadpudsa, S; Prasitsuebsai, W; Puthanakit, T; Sahakijpicharn, T; Srimuan, A; Techasaensiri, C; Thammajaruk, N | 1 |
| Burger, D; Colbers, A; Giaquinto, C; Gingelmaier, A; Hawkins, D; Hidalgo-Tenorio, C; Ivanovic, J; Kabeya, K; Lambert, J; Moltó, J; Rockstroh, J; Sadiq, ST; Taylor, G; van der Ende, M; Weizsäcker, K; Wyen, C | 1 |
| Aweeka, F; Baugh, BP; Benson, CA; Brown, TT; Cohn, SE; Currier, JS; Fichtenbaum, CJ; Godfrey, C; Haas, DW; Koletar, SL; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Patterson, KB; Presti, RM; Ribaudo, HJ; Rooney, JF; Sagar, M; Seekins, D | 1 |
| Amiel, C; Caseris, M; Charpentier, C; Descamps, D; Desnoyer, A; Farnoux, C; Lassel, L; Lê, MP; Pain, JB; Peytavin, G; Pialoux, G | 1 |
| Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
| Antela, A; Esteban, H; Estébanez, M; Mariño, A; Moreno, S; Navarro, J; Pasquau, J; Perez-Molina, JA; Riera, M; Rivero, A; Rubio, R; Santos, J; Sanz-Moreno, J; Suárez-Lozano, I; Troya, J | 1 |
| Abram, ME; Andrade-Villanueva, JF; Antunes, F; Arastéh, K; Cao, H; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, HC; Rizzardini, G; Szwarcberg, J | 1 |
| Ding, Y; Duan, J; Freeling, J; Ho, RJ; Koehn, J | 1 |
| Avihingsanon, A; Burger, D; Lewin, SR; Matthews, G; Punyawudho, B; Ruxrungtham, K; Thammajaruk, N; Thongpeang, P | 1 |
| Booth, JW; Post, FA | 1 |
| Cottrell, M; Dumond, JB; Forrest, A; Francis, O; Hudgens, MG; Malone, S; Mollan, K; Patterson, KB; Prince, HM; Sharpless, NE; Sykes, C; Torrice, C; Trezza, C; Van Dam, C; Wang, R; White, N | 1 |
| Fux, CA; Kirk, O; Lundgren, JD; Mocroft, A; Monforte, Ad; Moranne, O; Morlat, P; Reiss, P; Ross, M; Ryom, L | 1 |
| Chang, SC; Chang, SY; Hung, CC; Kuo, CH; Lin, SW; Liu, WC; Su, YC; Sun, HY; Tang, SY; Tsai, MS; Wu, BR | 1 |
| Bowman, VQ; Daar, ES; Diamond, C; Dube, MP; Goicoechea, M; Haubrich, RH; Jain, S; Karris, MY; Kemper, C; Kerkar, S; Morris, S; Rieg, G; Sun, X | 1 |
| Díez-García, LF; Gálvez-Contreras, MC; Romero-León, JM | 1 |
| Jones, R; Levy, JB; Milburn, J | 1 |
| Cavadas, C; Costa, S; do Céu Sousa, M; Machado, M | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Johnson, M; Kityo, C; Koenig, E; Squires, K; Szwarcberg, J; Voronin, E; White, K | 1 |
| Dahlby, JS; Guillemi, SA; Harris, M; Hogg, RS; Hull, MW; Lima, VD; Ling, SH; Montaner, JS; Werb, R; Yip, B; Zhang, W | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TTT; Yang, OO | 1 |
| Post, FA | 1 |
| Ganase, B; Guillemi, SA; Harrigan, PR; Harris, M; Hull, MW; Saeedi, R; Watson, B; Zhang, W | 1 |
| Cattaneo, D; Gervasoni, C; Pezzani, D; Resnati, C; Riva, A | 1 |
| Incardona, F; Meini, G; Mloka, D; Mugusi, F; Mugusi, S; Neogi, U; Sönnerborg, A; Svärd, J; Zazzi, M | 1 |
| Bonito, A; Bonora, S; Calcagno, A; Casari, S; Castelli, F; D'Avolio, A; Di Perri, G; Domenighini, E; Focà, E; Quiros Roldan, E; Simiele, M; Trentini, L | 1 |
| Amiel, C; Chaix, ML; Charpentier, C; Delaugerre, C; Descamps, D; Dufayard, J; Flandre, P; Grude, M; Guinard, J; Lambert-Niclot, S; Le Guillou-Guillemette, H; Maillard, A; Marcelin, AG; Mirand, A; Montes, B; Morand-Joubert, L; Mourez, T; Reigadas, S; Rodallec, A; Vallet, S | 1 |
| Borghetti, A; Castelli, F; Izzo, I; Lombardi, F; Maggiolo, F; Magro, P; Quiros-Roldan, E; Raffetti, E; Saracino, A | 1 |
| Ho, RJY; Koehn, J; Kraft, JC; McConnachie, LA; Perazzolo, S; Shen, DD; Shireman, LM | 1 |
| Firląg-Burkacka, E; Grycner, E; Horban, A; Kowalska, JD; Matłosz, B; Pietraszkiewicz, E | 1 |
| Edelstein, H; Maruff, P; Robertson, K; Ross, LL; Shaefer, MS; Small, CB; Wohl, D | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Bani-Sadr, F; Berger, JL; Brunet, A; Favarel-Garrigues, M; Hentzien, M | 1 |
| Adamson, L; Akkina, R; Blake, K; Burgunder, EM; Devanathan, AS; Garcia, JV; Kashuba, ADM; Kovarova, M; Luciw, P; Pirone, JR; Remling-Mulder, L; Rosen, EP; Schauer, AP; Srinivas, N; Sykes, C; White, NR | 1 |
| Foresto, RD; Kirsztajn, GM; Reghine, ÉL | 1 |
| El Kamari, V; Hileman, CO; Kosco, J; Mccomsey, GA | 1 |
| Acosta, S; Balogun, K; Guzman Lenis, MS; Mount, HT; Sarkar, A; Serghides, L | 1 |
| Chawana, TD; Ngara, B; Nhachi, CFB; Rusakaniko, S; Zvada, S | 1 |
| Chaudhary, NS; Funderburg, N; Irvin, MR; Kind, T; Overton, ET; Saag, MS; Shrestha, S; Wiener, HW; Willig, AL | 1 |
| Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI | 1 |
| Blanco, JL; Callau, P; de la Mora, L; de Lazzari, E; Gonzalez-Cordón, A; Inciarte, A; Laguno, M; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Rojas, J; Subirana, M; Torres, B | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
10 review(s) available for atazanavir sulfate and tenofovir
| Article | Year |
|---|---|
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Management of HIV-infected patients with multidrug-resistant virus.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Oligopeptides; Organophosphonates; Peptide Fragments; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2004 |
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Topics: Adenine; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir | 2005 |
An update and review of antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Drugs, Investigational; Emtricitabine; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oligopeptides; Organophosphates; Organophosphonates; Patient Compliance; Peptide Fragments; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir | 2006 |
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Renal disease associated with antiretroviral therapy in the treatment of HIV.
Topics: Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Indinavir; Kidney Diseases; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2011 |
Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir).
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Male; Middle Aged; Oligopeptides; Organophosphonates; Psoriasis; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
Managing chronic kidney disease in the older adults living with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chronic Disease; Darunavir; Drug Substitution; HIV Infections; Humans; Kidney; Kidney Diseases; Lopinavir; Middle Aged; Tenofovir | 2017 |
HIV-related nephropathy: new aspects of an old paradigm.
Topics: Acute Kidney Injury; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chronic Disease; HIV Infections; Humans; Kidney; Risk Factors; Tenofovir | 2020 |
53 trial(s) available for atazanavir sulfate and tenofovir
| Article | Year |
|---|---|
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Area Under Curve; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridines; Ritonavir; Spectrophotometry, Ultraviolet; Tenofovir | 2004 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Drug Administration Schedule; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Viral Load | 2005 |
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Time Factors; Treatment Outcome | 2006 |
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Salvage Therapy; Tenofovir; Treatment Failure | 2006 |
Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
Topics: Adenine; Adult; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; Humans; Kidney; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Creatinine; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Male; Middle Aged; Models, Biological; Oligopeptides; Organophosphonates; Prognosis; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2007 |
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Atazanavir Sulfate; Chromatography, Liquid; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Matched-Pair Analysis; Metabolic Clearance Rate; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Time Factors; Treatment Outcome | 2007 |
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Furans; Genetic Variation; HIV Infections; HIV-1; Humans; Middle Aged; Oligopeptides; Organophosphates; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Sequence Analysis, RNA; Sulfonamides; Tenofovir; Treatment Failure | 2010 |
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Irritable Bowel Syndrome; Lopinavir; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Pyrimidinones; Quality of Life; Ritonavir; Surveys and Questionnaires; Tenofovir; Young Adult | 2010 |
Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Oligopeptides; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Urolithiasis | 2011 |
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemias; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Child; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2011 |
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Famotidine; Female; Histamine H2 Antagonists; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Oligopeptides; Organophosphonates; Pyridines; Saquinavir; Tenofovir; Treatment Outcome | 2011 |
Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Central African Republic; DNA Fingerprinting; Drug Resistance, Viral; Female; Genetic Variation; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load; Young Adult; Zidovudine | 2012 |
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Creatinine; Cyclopropanes; Cystatin C; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir | 2012 |
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cognition; Cognition Disorders; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Zidovudine | 2012 |
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; C-Reactive Protein; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV-1; Humans; Inflammation; Interleukin-6; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tumor Necrosis Factor-alpha | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; Tenofovir; Thiazoles | 2012 |
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Alleles; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Deoxycytidine; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Middle Aged; Models, Biological; Nonlinear Dynamics; Oligopeptides; Organophosphonates; Pharmacogenetics; Pyridines; Ritonavir; Tenofovir; Young Adult | 2012 |
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Female; Genitalia, Female; HIV Infections; Humans; Lamivudine; Models, Biological; Oligopeptides; Organophosphonates; Premenopause; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Triazoles; Viral Load; Young Adult | 2013 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides | 2013 |
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2013 |
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Ritonavir; Surveys and Questionnaires; Tenofovir; Viral Load | 2013 |
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2013 |
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Asian People; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrrolidines; Ritonavir; Tenofovir; Valine; Viral Nonstructural Proteins; Young Adult | 2013 |
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tomography, X-Ray Computed; Young Adult | 2014 |
Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
Topics: Adolescent; Adult; Area Under Curve; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Gestational Age; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Pregnancy; Pregnancy Trimester, Third; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Tenofovir; Therapeutic Equivalency; Viral Load | 2014 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Zidovudine | 2015 |
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Viral Load | 2015 |
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Australia; Europe; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Tenofovir; United States; Young Adult | 2016 |
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2016 |
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cobicistat; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; International Cooperation; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2016 |
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carotid Intima-Media Thickness; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Raltegravir Potassium; Ritonavir; RNA, Viral; Tenofovir | 2017 |
Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; CD4 Lymphocyte Count; Drug Substitution; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cognition; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Prospective Studies; Ritonavir; Tenofovir | 2019 |
Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe.
Topics: Adolescent; Anti-Retroviral Agents; Atazanavir Sulfate; Caregivers; Female; Hair; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Models, Biological; Overweight; Ritonavir; Tenofovir; Thinness; Viral Load; Zimbabwe | 2021 |
An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Topics: Adenosine Monophosphate; Adult; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Healthy Volunteers; Humans; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Tenofovir; Uganda | 2021 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
73 other study(ies) available for atazanavir sulfate and tenofovir
| Article | Year |
|---|---|
Promising new agents on the horizon.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2002 |
New antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Deoxycytidine; Dioxolanes; Drugs, Investigational; Emtricitabine; Furans; Guanosine; HIV Fusion Inhibitors; Humans; Imidazoles; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Prodrugs; Protease Inhibitors; Pyridines; Pyrones; Quinazolines; Reverse Transcriptase Inhibitors; Sulfonamides; Sulfur Compounds; Tenofovir | 2001 |
BMS issues PK notice regarding ATV + TDF.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Clinical Trials as Topic; Drug Industry; HIV Infections; Humans; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridines; Tenofovir; United States; United States Food and Drug Administration | 2003 |
Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.
Topics: Adenine; Atazanavir Sulfate; Carbolines; Drug Information Services; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Imidazoles; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Piperazines; Purines; Pyridines; Reverse Transcriptase Inhibitors; Sildenafil Citrate; Sulfones; Tadalafil; Tenofovir; Triazines; Vardenafil Dihydrochloride | 2004 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2006 |
Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Bias; Cross-Over Studies; Drug Interactions; France; HIV Infections; Humans; Likelihood Functions; Nonlinear Dynamics; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2007 |
Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Ritonavir; Tenofovir; Virus Replication | 2006 |
Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Fluorescent Antibody Technique; HIV Infections; Humans; Immunohistochemistry; Kidney; Male; Microscopy, Electron; Middle Aged; Nephritis, Interstitial; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Tenofovir | 2007 |
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
Topics: Adenine; Adult; Adverse Drug Reaction Reporting Systems; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Hospitalization; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States | 2007 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2008 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Urolithiasis; Viral Load | 2008 |
[Acute renal failure associated with the use of tenofovir combined with atazanavir in patients with HIV infection].
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2008 |
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2008 |
96-week CASTLE data show similar efficacy results.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2008 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Atazanavir-related renal insufficiency without concurrent tenofovir.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2009 |
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Dyslipidemias; Emtricitabine; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oligopeptides; Organophosphonates; Pravastatin; Pyridines; Rhabdomyolysis; Ritonavir; Tenofovir | 2009 |
Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; History, 17th Century; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2009 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
[Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
Topics: Adenine; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Randomized Controlled Trials as Topic; Tenofovir | 2010 |
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Disease Progression; Epidemiologic Methods; Female; Glomerular Filtration Rate; HIV Seropositivity; HIV-1; Humans; Indinavir; Kidney Failure, Chronic; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; London; Male; Oligopeptides; Organophosphonates; Pyridines; Risk Factors; Tenofovir | 2010 |
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chagas Disease; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nitroimidazoles; Oligopeptides; Organophosphonates; Paraguay; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Spain; Tenofovir; Trypanocidal Agents; Zidovudine | 2011 |
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Markov Chains; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Tenofovir; United States | 2011 |
Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cross-Sectional Studies; Fanconi Syndrome; Female; France; HIV Infections; HIV-1; Humans; Kidney Tubules, Proximal; Logistic Models; Male; Middle Aged; Odds Ratio; Oligopeptides; Organophosphonates; Prevalence; Pyridines; Risk Assessment; Risk Factors; Tenofovir; Time Factors | 2011 |
Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
Topics: Adenine; Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; HIV Infections; Humans; Male; Models, Biological; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tissue Distribution | 2011 |
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2011 |
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2011 |
Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy.
Topics: Adenine; Adrenal Insufficiency; Adult; Atazanavir Sulfate; Cushing Syndrome; Cytochrome P-450 Enzyme Inhibitors; Female; HIV Protease Inhibitors; HIV Seropositivity; Humans; Iatrogenic Disease; Injections, Intramuscular; Lamivudine; Oligopeptides; Organophosphonates; Pruritus; Pyridines; Ritonavir; Tenofovir; Triamcinolone Acetonide | 2011 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Epidemiologic Methods; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Mexico; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Immune reconstitution renal-limited sarcoidosis presenting as acute kidney injury.
Topics: Acute Kidney Injury; Adenine; Adult; AIDS-Associated Nephropathy; Anti-Retroviral Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Oligopeptides; Organophosphonates; Prednisone; Pyridines; Ritonavir; Sarcoidosis; Tenofovir; Young Adult | 2012 |
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Cutaneous CD8+ T-cell infiltrates associated with human immunodeficiency virus.
Topics: Adenine; Alopecia; Anti-HIV Agents; Antigens, Differentiation, T-Lymphocyte; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD8-Positive T-Lymphocytes; Deoxycytidine; Diagnosis, Differential; Emtricitabine; HIV Infections; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Oligopeptides; Organophosphonates; Prednisone; Pseudolymphoma; Pyridines; Ritonavir; Skin; Tenofovir | 2012 |
Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Denmark; Female; Glomerular Filtration Rate; HIV Infections; Humans; Incidence; Kidney; Linear Models; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Renal Insufficiency, Chronic; Tenofovir | 2012 |
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2012 |
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time Factors | 2013 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Proteinuria; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2013 |
Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; HIV Infections; Humans; Liver Function Tests; Male; Nephrectomy; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2013 |
Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.
Topics: Adenine; Animals; Anti-HIV Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Drug Interactions; Humans; Intestinal Absorption; Intestinal Mucosa; Male; Oligopeptides; Organic Anion Transporters; Organophosphonates; Permeability; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Tenofovir | 2013 |
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Chromatography, Liquid; Cross-Sectional Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2013 |
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American; Cyclopropanes; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; Female; Frail Elderly; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; White People | 2013 |
Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir.
Topics: Adenine; Adult; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; Female; Genotype; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Viral Load | 2013 |
Boosting HIV treatment options: good news, new challenges.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles | 2013 |
Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Comorbidity; Denmark; Female; HIV Infections; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Renal Dialysis; Renal Replacement Therapy; Risk Factors; Tenofovir | 2014 |
Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Combinations; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir | 2013 |
Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles.
Topics: Adenine; Animals; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Lipids; Macaca nemestrina; Oligopeptides; Organophosphonates; Pyridines; Sulfonamides; Tenofovir | 2014 |
Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Child; Female; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2014 |
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Emtricitabine; Female; Glucuronosyltransferase; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Male; Oxazines; Piperazines; Pregnancy; Pyridones; Ritonavir; Tenofovir | 2015 |
A simple, efficient, and sensitive method for simultaneous detection of anti-HIV drugs atazanavir, ritonavir, and tenofovir by use of liquid chromatography-tandem mass spectrometry.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Chromatography, Liquid; HIV Infections; Humans; Ritonavir; Tandem Mass Spectrometry; Tenofovir | 2015 |
Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Coinfection; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Models, Biological; Nonlinear Dynamics; Renal Elimination; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thailand; Treatment Outcome | 2015 |
HIV and the kidney in the acute medical unit.
Topics: Acute Kidney Injury; Anti-Retroviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Tenofovir | 2015 |
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.
Topics: Adult; Aged; Aging; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclin-Dependent Kinase Inhibitor p16; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Gene Expression; HIV Infections; Humans; Male; Middle Aged; Nucleotides; Ritonavir; Tenofovir; Young Adult | 2016 |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic st
Topics: Adult; Aged; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Drug Combinations; Drug Monitoring; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lamivudine; Male; Middle Aged; Peroxisome-Targeting Signal 1 Receptor; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2017 |
Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Benzazepines; Bradycardia; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Emtricitabine; Female; Heart Failure; HIV Infections; Humans; Ivabradine; Middle Aged; Ritonavir; Tenofovir | 2016 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred BALB C; Nevirapine; Phosphorylcholine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Tenofovir; Viral Load | 2016 |
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Gastrectomy; HIV Infections; Humans; Male; Middle Aged; Tenofovir | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Decision-Making; Computational Biology; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Monitoring, Physiologic; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Stavudine; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2017 |
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Leukocytes, Mononuclear; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimesters; Prospective Studies; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Topics: Adult; Atazanavir Sulfate; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Retrospective Studies; Tenofovir; Treatment Failure; Viral Load | 2018 |
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4-CD8 Ratio; Cohort Studies; Darunavir; Dideoxynucleosides; Female; HIV Infections; Humans; Inflammation; Italy; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; HIV Infections; Humans; Leukocytes, Mononuclear; Lipids; Lymphocytes; Macaca nemestrina; Male; Nanoparticles; Ritonavir; Tenofovir | 2018 |
Risk factors for kidney disease among HIV-1 positive persons in the methadone program.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Indinavir; Kidney Diseases; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Poland; Risk Factors; Sex Factors; Tenofovir; Time Factors | 2019 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Life-threatening rhabdomyolysis and Fanconi syndrome related to tenofovir disoproxil fumarate administration in an HIV-infected patient.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Fanconi Syndrome; Fluid Therapy; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Rhabdomyolysis; Tenofovir | 2020 |
Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs.
Topics: Animals; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Emtricitabine; Female; HIV Infections; Humans; In Vitro Techniques; Maraviroc; Mice; Raltegravir Potassium; Tenofovir | 2019 |
Sleeve Gastrectomy Compared With Roux-en-Y Gastric Bypass in Individuals Living With HIV.
Topics: Adult; Atazanavir Sulfate; Body Mass Index; Gastrectomy; Gastric Bypass; HIV Infections; Humans; Middle Aged; Obesity; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Developmental Disabilities; Dideoxynucleosides; Emtricitabine; Exploratory Behavior; Female; Fetal Growth Retardation; Growth Disorders; Hand Strength; HIV Protease Inhibitors; Homing Behavior; Lamivudine; Male; Mice; Mice, Inbred C57BL; Pregnancy; Prenatal Exposure Delayed Effects; Random Allocation; Reflex, Abnormal; Reflex, Righting; Sensation Disorders; Taxis Response; Tenofovir | 2020 |
Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study.
Topics: Adult; Anti-Retroviral Agents; Atazanavir Sulfate; Chi-Square Distribution; Darunavir; Female; HIV Infections; Humans; Lipidomics; Lipids; Male; Mass Spectrometry; Middle Aged; Plasma; Raltegravir Potassium; Tenofovir | 2021 |
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Tenofovir | 2022 |